(Q38648765)

5 September 2017

0 references

HER2-positive breast cancer is lost in translation: time for patient-centered research (English)

1 reference

5 September 2017

3

Evandro de Azambuja

1 reference

5 September 2017

Isabelle Gingras

1

1 reference

5 September 2017

Géraldine Gebhart

series ordinal

2

1 reference

5 September 2017

Martine Piccart-Gebhart

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

1 August 2017

1 reference

Nature Reviews Clinical Oncology

5 September 2017

published in

1 reference

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

The immune system and response to HER2-targeted treatment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Why your preferred targeted drugs may become unaffordable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Neoadjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Quantitative reverse transcriptase polymerase chain reaction and the Oncotype DX test for assessment of human epidermal growth factor receptor 2 status: time to reflect again?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Deconstructing the molecular portraits of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Predictive factors for response to neoadjuvant therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Her2 cross talk and therapeutic resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Mutational processes molding the genomes of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Very high quantitative tumor HER2 content and outcome in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

HER2 status and benefit from adjuvant trastuzumab in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

7 January 2021

inferred from DOI database lookup

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.96

7 January 2021

inferred from DOI database lookup

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer

1 reference

12 December 2020

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence

1 reference

12 December 2020

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

1 reference

12 December 2020

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

1 reference

12 December 2020

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

1 reference

12 December 2020

Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples

1 reference

12 December 2020

10.1038/NRCLINONC.2017.96

Identifiers

DOI

1 reference

5 September 2017

1 reference